BUZZ-Morgan Stanley sees EPS accretion to CSL's buyout of Vifor Pharma** Morgan Stanley says CSL's acquisition of Vifor Pharma is expected to imply a 6.6% earnings-per-share accretion to its FY23 estimate
** The biotechnology firm said on Tuesday acquisition of Vifor Pharma AG is expected to be completed by Aug 9 [nFWN2ZD61S]
** Broker sees merit in buyout due to diversification of co's portfolio against potential medium- to long-term disruption from 'FcRn' and influenza vaccine manufactured by mRNA technology, among others
** Broker estimates CSL's plasma collections to return to pre-pandemic levels in March-quarter 2022 and expects volumes to rise more than 20% pcp in FY23
** Brokerage keeps "overweight" rating on the stock, sets a price target of A$312.00
** Fourteen of 15 analysts rate the stock "buy" or higher, one "hold" and none "sell" or lower; their median PT is A$327.63
– Refinitiv data
** CSL shares drop 0.4%, in line with a weak broader market <.AXJO>, which is down 0.5%
** CSL stock up 2.1% this year, as of last close
copy and past
CSL - $300 and beyond, page-29
-
- There are more pages in this discussion • 85 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$308.53 |
Change
3.060(1.00%) |
Mkt cap ! $149.0B | |||
| Open | High | Low | Value | Volume |
| $308.99 | $308.99 | $305.97 | $232.7M | 769.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 913 | $307.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $308.59 | 20 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| CSL (ASX) Chart |